Skip to main content
Top
Published in: Current Heart Failure Reports 6/2017

01-12-2017 | Prevention of Heart Failure (M. St. John Sutton, Section Editor)

Pulmonary Hypertension Due to Left Ventricular Cardiomyopathy: Is it the Result or Cause of Disease Progression?

Authors: Srinath Adusumalli, Jeremy A. Mazurek

Published in: Current Heart Failure Reports | Issue 6/2017

Login to get access

Abstract

Purpose of Review

The purpose of this review is to define pulmonary hypertension in the setting of left heart disease (PH-LHD), discuss its epidemiology and pathophysiology, and highlight the cause and effect relationship it has with disease progression in the setting of cardiomyopathy.

Recent Findings

Both pulmonary hypertension (PH) and heart failure are becoming increasingly common. As such, PH-LHD is now the most common form of PH. The pathophysiology of the condition relates to backward transmission of elevated left ventricular filling pressures into the pulmonary circulation and, ultimately, right ventricular (RV) strain/dysfunction. It is evident that these pathophysiologic processes are both the effect and cause of left heart disease progression.

Summary

In this review, we describe the complex relationship between disease progression in left ventricular cardiomyopathy and PH-LHD. Clinicians and researchers should take note of the importance of PH-LHD and RV dysfunction to appropriately risk stratify patients and develop therapies for the condition.
Literature
4.
go back to reference •• Galiè N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertensionThe Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67–119. https://doi.org/10.1093/eurheartj/ehv317. This is an excellent recent guideline document on the topic of pulmonary hypertension. CrossRefPubMed •• Galiè N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertensionThe Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67–119. https://​doi.​org/​10.​1093/​eurheartj/​ehv317. This is an excellent recent guideline document on the topic of pulmonary hypertension. CrossRefPubMed
9.
go back to reference Tedford RJ, Beaty CA, Mathai SC, Kolb TM, Damico R, Hassoun PM, et al. Prognostic value of the pre-transplant diastolic pulmonary artery pressure to pulmonary capillary wedge pressure gradient (DPG) in cardiac transplant recipients with pulmonary hypertension. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2014;33:289–97. https://doi.org/10.1016/j.healun.2013.11.008.CrossRef Tedford RJ, Beaty CA, Mathai SC, Kolb TM, Damico R, Hassoun PM, et al. Prognostic value of the pre-transplant diastolic pulmonary artery pressure to pulmonary capillary wedge pressure gradient (DPG) in cardiac transplant recipients with pulmonary hypertension. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2014;33:289–97. https://​doi.​org/​10.​1016/​j.​healun.​2013.​11.​008.CrossRef
37.
go back to reference Guazzi M, Bandera F, Pelissero G, Castelvecchio S, Menicanti L, Ghio S, et al. Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis. Am J Physiol - Heart Circ Physiol. 2013;305:H1373–81. https://doi.org/10.1152/ajpheart.00157.2013.CrossRefPubMed Guazzi M, Bandera F, Pelissero G, Castelvecchio S, Menicanti L, Ghio S, et al. Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis. Am J Physiol - Heart Circ Physiol. 2013;305:H1373–81. https://​doi.​org/​10.​1152/​ajpheart.​00157.​2013.CrossRefPubMed
41.
go back to reference Bosch L, Lam CSP, Gong L, Chan SP, Sim D, Yeo D, et al. Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction: right ventricular dysfunction in heart failure. Eur J Heart Fail. 2017; https://doi.org/10.1002/ejhf.873. Bosch L, Lam CSP, Gong L, Chan SP, Sim D, Yeo D, et al. Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction: right ventricular dysfunction in heart failure. Eur J Heart Fail. 2017; https://​doi.​org/​10.​1002/​ejhf.​873.
43.
go back to reference Ghio S, Guazzi M, Scardovi AB, Klersy C, Clemenza F, Carluccio E, et al. Different correlates but similar prognostic implications for right ventricular dysfunction in heart failure patients with reduced or preserved ejection fraction. Eur J Heart Fail. 2017;19:873–9. https://doi.org/10.1002/ejhf.664.CrossRefPubMed Ghio S, Guazzi M, Scardovi AB, Klersy C, Clemenza F, Carluccio E, et al. Different correlates but similar prognostic implications for right ventricular dysfunction in heart failure patients with reduced or preserved ejection fraction. Eur J Heart Fail. 2017;19:873–9. https://​doi.​org/​10.​1002/​ejhf.​664.CrossRefPubMed
44.
go back to reference Dini FL, Carluccio E, Simioniuc A, Biagioli P, Reboldi G, Galeotti GG, et al. Right ventricular recovery during follow-up is associated with improved survival in patients with chronic heart failure with reduced ejection fraction: right ventricular recovery in heart failure. Eur J Heart Fail. 2016;18:1462–71. https://doi.org/10.1002/ejhf.639.CrossRefPubMed Dini FL, Carluccio E, Simioniuc A, Biagioli P, Reboldi G, Galeotti GG, et al. Right ventricular recovery during follow-up is associated with improved survival in patients with chronic heart failure with reduced ejection fraction: right ventricular recovery in heart failure. Eur J Heart Fail. 2016;18:1462–71. https://​doi.​org/​10.​1002/​ejhf.​639.CrossRefPubMed
Metadata
Title
Pulmonary Hypertension Due to Left Ventricular Cardiomyopathy: Is it the Result or Cause of Disease Progression?
Authors
Srinath Adusumalli
Jeremy A. Mazurek
Publication date
01-12-2017
Publisher
Springer US
Published in
Current Heart Failure Reports / Issue 6/2017
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-017-0368-2

Other articles of this Issue 6/2017

Current Heart Failure Reports 6/2017 Go to the issue

Pathophysiology: Neuroendocrine, Vascular, and Metabolic Factors (S Katz, Section Editor)

Glycosylated Chromogranin A: Potential Role in the Pathogenesis of Heart Failure

Genetics of Heart Failure (K Adams, Section Editor)

Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure

Prevention of Heart Failure (M. St. John Sutton, Section Editor)

Defining Ambulatory Advanced Heart Failure: MedaMACS and Beyond

Pathophysiology: Neuroendocrine, Vascular, and Metabolic Factors (S Katz, Section Editor)

Skeletal muscle alterations in HFrEF vs. HFpEF

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.